High-dose Cholecalciferol Supplementation in Adults with Cystic Fibrosis
Janzen KM, Sakon C, Lehman A, Sommer B, Brown C
Pharmacotherapy · 2 citations
How it was studied
- Design
- Controlled clinical trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Indiana University Health
Based on 1 listed funder(s).
Publication
- Published
- 2019-07-06 · Pharmacotherapy · vol. 39 · issue 9 · pp. 874–880
- Publisher
- Wiley
- Cited
- 7 citations · more than 76% of similar papers · 0.9× the field average
- References
- 11 works
- Access
- Free to read
- Research areas
- Cystic Fibrosis Research Advances · Vitamin D Research Studies · Pancreatitis Pathology and Treatment
- Keywords
- Cholecalciferol, Medicine, Vitamin D and neurology, vitamin D deficiency, Cystic fibrosis, Internal medicine, Gastroenterology, Population, Dosing
- MeSH
- humans, cystic fibrosis, exocrine pancreatic insufficiency, vitamin d deficiency, cholecalciferol, vitamins, prospective studies, dose-response relationship, drug, dietary supplements, adult, female, male, young adult
5 authors
From US
- Kristin M. Janzen · correspondingIndiana University Health; Indiana University – Purdue University Indianapolis
- Colleen M. SakonIndiana University Health; Indiana University – Purdue University Indianapolis
- Angela LehmanIndiana University Health; Indiana University – Purdue University Indianapolis
- Bekah SommerIndiana University Health; Indiana University – Purdue University Indianapolis
- Cynthia D. BrownIndiana University Health; Indiana University School of Medicine; Indiana University – Purdue University Indianapolis
Abstract
Introduction
Despite the availability of consensus guidelines for the treatment of vitamin D deficiency, prospective trials are lacking to examine alternative dosing strategies for adult patients with cystic fibrosis (CF) who do not meet therapeutic goals with standard regimens.
Objectives
The primary objective of this study was to determine the efficacy of high-dose cholecalciferol supplementation in increasing serum vitamin D (25-OHD) levels in adult patients with CF.
Methods
Patients were eligible for inclusion if they were 18 years or older, had baseline 25-OHD levels lower than 30 ng/ml, and were diagnosed with CF and pancreatic insufficiency. Patients were given a single dose of cholecalciferol 300,000 or 500,000 IU based on baseline 25-OHD levels. Response was defined by 25-OHD and ionized calcium levels at 3 months. At 6 months, responders received a second dose of the same strength, and nonresponders were given a weekly supplement of cholecalciferol 50,000 IU in addition to cholecalciferol 500,000 IU. A second 25-OHD level was obtained at 9 months.
Results
Of the 46 patients enrolled, 32 patients (70%) completed the study. Baseline levels of 25-OHD significantly increased over time in the per protocol population at 3 and 9 months. A total of 16 patients (50%) were considered nonresponders and required weekly supplementation.
Conclusion
A protocol using high-dose cholecalciferol or high-dose plus weekly cholecalciferol is safe and effective in treating adult patients with CF and pancreatic insufficiency.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.